Ravidasvir (PPI-668) is an investigational
NS5A inhibitor (by
Pharco Pharmaceuticals) in
clinical trial
Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietar ...
s for chronic
hepatitis C
Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver; it is a type of viral hepatitis. During the initial infection people often have mild or no symptoms. Occasionally a fever, dark urine, a ...
genotype 4.
Preliminary clinical trial results were announced in Nov 2015. In April 2017, press reports stated that a combination treatment involving ravidasvir and
sofosbuvir
Sofosbuvir, sold under the brand name Sovaldi among others, is a medication used to treat hepatitis C. It is taken Oral administration, by mouth.
Common side effects include fatigue, headache, nausea, and trouble sleeping. Side effects are gen ...
had achieved a 97% clearup rate against hepatitis C in a clinical trial conducted in Malaysia and Thailand, and 100% in another conducted in Egypt. It has been granted conditional registration by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia.
See also
*
Discovery and development of NS5A inhibitors
Nonstructural protein 5A (NS5A) inhibitors are direct acting antiviral agents (DAAs) that target viral proteins, and their development was a culmination of increased understanding of the viral life cycle combined with advances in drug discovery te ...
References
Experimental drugs
Gilead Sciences
NS5A inhibitors
{{antiinfective-drug-stub